加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$7.84
−US$0.24 · -2.97%
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
前收盘价
US$7.84
−US$0.24 · -2.97%
盘后
US$7.84
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
日内区间
当前US$7.84
52周区间
当前US$7.84
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
87
深度低估
情绪
54
多空交织
风险
33
中等风险
动量
31
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
日内区间
当前US$7.84
52周区间
当前US$7.84
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.8亿 USD | 1.61亿 USD | 1.43亿 USD | 1.29亿 USD | 1.04亿 USD |
| 销货成本 | 1.04亿 USD | 9098.6万 USD | 8702.9万 USD | 8263.6万 USD | 7331.4万 USD |
| 毛利 | 7640.7万 USD | 6996.7万 USD | 5549万 USD | 4670.3万 USD | 3032.8万 USD |
| 研究与开发 | 1299.5万 USD | 1518.5万 USD | 1393.3万 USD | 1317.2万 USD | 1135.7万 USD |
| 销售、一般及管理费用 | 3384.1万 USD | 3083.4万 USD | 2744.9万 USD | 2505.8万 USD | 1755.1万 USD |
| 营业费用 | 5017.4万 USD | 4991.6万 USD | 4542.6万 USD | 4217.1万 USD | 3102.4万 USD |
| 利息收入 | 192.1万 USD | 211.8万 USD | 58.8万 USD | 9.1万 USD | 29.5万 USD |
| 利息支出 | 86.4万 USD | 66万 USD | 129.8万 USD | 91.4万 USD | 28.3万 USD |
| 折旧和摊销 | 1491.8万 USD | 1380.8万 USD | 1271.4万 USD | 1215.5万 USD | 560.9万 USD |
| 营业利润 | 2623.3万 USD | 2005.1万 USD | 1006.4万 USD | 453.2万 USD | −69.6万 USD |
| 净利润 | 2019.8万 USD | 1446.2万 USD | 828.4万 USD | −232.1万 USD | −223万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年8月27日 | US$0.17Semi-Annual | 2026年8月27日 | 2026年9月17日 |
股息 | 2026年3月23日 | US$0.25Irregular | 2026年3月23日 | 2026年4月7日 |
股息 | 2025年3月17日 | US$0.1998Special | 2025年3月17日 | 2025年4月7日 |
除息 2026年8月27日
US$0.17
Semi-Annual
2026年8月27日登记 · 支付日 2026年9月17日
除息 2026年3月23日
US$0.25
Irregular
2026年3月23日登记 · 支付日 2026年4月7日
除息 2025年3月17日
US$0.1998
Special
2025年3月17日登记 · 支付日 2025年4月7日
报告持有此股票敞口的交易所交易基金。
Dimensional - International Small Cap Value ETFDISV37.9万0.01%50.56亿 USD0.42%US$42.50-0.34%
Dimensional - International Small Cap ETFDFIS32.64万0.01%57.5亿 USD0.39%US$35.93-0.28%
Dimensional - International Core Equity 2 ETFDFIC28.07万0.00%150.17亿 USD0.22%US$37.47-0.16%
Acuitas Small Cap Active ETFAIMS18.82万0.22%8393万 USD0.75%US$27.06-0.11%
Dimensional World ex U.S. Core Equity 2 ETFDFAX10.38万0.00%123.36亿 USD0.28%US$36.92-0.43%
Invesco Nasdaq Biotechnology ETFIBBQ3.55万0.03%1.12亿 USD0.19%US$34.2482-1.07%
ProShares Ultra Nasdaq BiotechnologyBIB1.74万0.02%9138.97万 USD1.19%US$108.79-1.90%Dimensional - International Small Cap Value ETFDISVDimensional - International Small Cap ETFDFISDimensional - International Core Equity 2 ETFDFICAcuitas Small Cap Active ETFAIMSDimensional World ex U.S. Core Equity 2 ETFDFAXInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
